Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This research was published in Nature.
Governor Hochul signed a bipartisan bill to ensure access to biomarker testing and the right treatment for cancer and other illnesses.
This research was published in Cell.
Simple CUT&Tag adaptation gives information about genetic regulatory elements in formalin-fixed tumor samples
A study in mice found that engineered "bacterial biosensors” could detect DNA shed by colorectal cancer tumors.
These bacteria can promote the development of colorectal cancer by damaging DNA and hindering the body’s immune system.
New research links mutations in an RNA region that helps regulate protein production to progression and drug resistance.
Researchers unveil a less toxic, more efficient method to genetically engineer immune cells that target tumor cells.
Team uses large-scale proteogenomic changes to identify which ovarian cancer patients should look beyond standard treatment options.
And learn about the cutting-edge work of these early-career physician-scientists named the 2023 Damon Runyon Clinical Investigators.
As males grow older, some of their cells may naturally lose the Y chromosome. This may affect bladder cancer protection and treatment.
Galleri is the first of a wave of multi-cancer early-detection tests that analyze DNA fragments in the blood for abnormalities.
Germline testing, especially for certain breast, ovarian, pancreatic and prostate cancers, can guide treatment choices.
The approval makes Talzenna (talazoparib) the third PARP-blocking drug to be cleared by the FDA to treat prostate cancer.
Learn more about melanoma risk factors, hereditary melanoma, and genetic testing.
Measurable traits, such as genetic mutations, can guide treatment and help predict outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.